Cargando…

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

BACKGROUND: Colchicine has been proposed as a treatment for COVID-19 based on its anti-inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients admitted to hospital with COVID-19. METHODS: In this streamlined, randomised, controlled, open-label trial, underway at...

Descripción completa

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523117/ https://www.ncbi.nlm.nih.gov/pubmed/34672950 http://dx.doi.org/10.1016/S2213-2600(21)00435-5

Ejemplares similares

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2021)

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2021)

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2022)

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2020)

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2022)

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Publicado: (2021)

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Publicado: (2022)

Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
por: Eikelboom, John W, et al.
Publicado: (2022)

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2023)

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
por: Eikelboom, John W, et al.
Publicado: (2022)

Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
por: Dorward, Jienchi, et al.
Publicado: (2022)

Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial
por: Rahhal, Alaa, et al.
Publicado: (2022)

Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial
por: Lacombe, Karine, et al.
Publicado: (2023)

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial
por: Lopes, Renato D, et al.
Publicado: (2021)

Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
por: Cohen, Jordana B, et al.
Publicado: (2021)

A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection
por: Sandhu, Tegveer, et al.
Publicado: (2020)

Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials
por: Mehta, Kedar Gautambhai, et al.
Publicado: (2021)

Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial
por: Gaitán-Duarte, H.G., et al.
Publicado: (2021)

Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care
por: Roddy, Edward, et al.
Publicado: (2020)

Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID)
por: Pascual-Figal, Domingo A, et al.
Publicado: (2021)

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
por: Hung, Ivan Fan-Ngai, et al.
Publicado: (2020)

Treatment with COLchicine in hospitalized patients affected by COVID-19: The COLVID-19 trial
por: Perricone, Carlo, et al.
Publicado: (2023)

Effect of colchicine on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials
por: Lan, Shao-Huan, et al.
Publicado: (2022)

An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance: Study protocol for investigator-initiated, multicenter, open-label trial
por: Koga, Tomohiro, et al.
Publicado: (2020)

Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
por: Hayward, Gail, et al.
Publicado: (2021)

Colchicine in patients with heart failure and preserved left ventricular ejection fraction: rationale and design of a prospective, randomised, open-label, crossover clinical trial
por: Shchendrygina, Anastasia, et al.
Publicado: (2023)

29. Sustained Recovery in Patients Admitted to Hospital With COVID-19
por: Moestrup, Kasper S, et al.
Publicado: (2021)

Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial
por: Sekhavati, Ehsan, et al.
Publicado: (2020)

Massive Colchicine Overdose with Recovery
por: Iosfina, Ioulia, et al.
Publicado: (2012)

Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
Publicado: (2023)

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
por: Ader, Florence, et al.
Publicado: (2022)

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
por: Yu, Ly-Mee, et al.
Publicado: (2021)

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Publicado: (2022)

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
por: Bégin, Philippe, et al.
Publicado: (2021)

Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
por: Lopes, Maria Isabel, et al.
Publicado: (2021)

Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
por: Sekine, Leo, et al.
Publicado: (2022)

Safety and efficacy of Siddha management as adjuvant care for COVID-19 patients admitted in a tertiary care hospital - An open-label, proof-of-concept Randomized Controlled Trial
por: Christian, Gnanaraj Johnson, et al.
Publicado: (2023)

Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19)
por: Brodin, Daniel, et al.
Publicado: (2023)

Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial
por: Li, Guoming, et al.
Publicado: (2021)

Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
por: Brunetti, Luigi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h2o76f7n8iaqmfiehbvcgn5qmh